This is a fairly even and well thought out piece but the author does seem to be a fan of 23andme: the author suggests that the FDA should have contacted 23andme semi-formally before because 23andme has a high turnover and their senior management is having a tough personal time. This is a bit funny. The author is basically suggesting that the management of 23andme is incompetent and the FDA needs to make allowances for this incompetence.

Otherwise the article nicely lays out the tensions between consumer advocacy, scientific rigor and sales.